Amgen Inc.
Company Snapshot
Company Overview
Amgen discovers, develops, manufactures, and distributes innovative human therapeutics. The company offers therapeutics for diseases like cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen focuses on developing novel products based on recombinant DNA and molecular biology advances. It has a presence in over 100 countries worldwide.
The company has the most significant sales and marketing network in the U.S. and Europe. However, Amgen is expanding its commercial operations in Latin America, Japan, China, and the Middle East. In March 2022, the company introduced a new manufacturing plant in North Carolina, U.S., to increase its manufacturing network capacity. Amgen operates in one business segment: human therapeutics.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Product sales : Prolia, ENBREL, Otezla, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA and Other products
- Other revenues : Royalty income and corporate partner revenues.
Applications/End User Industries
- Production of White Blood Cells
- Chemotherapy
- Reducing the Risk of Infectio
- Treatment for Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Stimulate Red Blood Cell Production
- Anemia
- Chronic Kidney Disease
- Novel Therapies
- Academic Institutions
- CGD Specialist
- Aimovig
- Migraine
- Nephrology
- Oncology
- Melanoma
- Drug Development
